Head-to-head · WeighScore
Dr. Gillis' Wellness Center vs Tablet Health
The verdict
Dr. Gillis' Wellness Center takes it — 67/100 to 47.6/100.
Dr. Gillis' Wellness Center grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Dr. Gillis' Wellness Center is a Maine-based clinic (Oakland) offering nationwide telehealth for GLP-1 weight loss. It prescribes semaglutide, tirzepatide, and retatrutide in both injectable and subli
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Dr. Gillis' Wellness Center | Tablet Health |
|---|---|---|
| WeighScore | 67/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #169 | #495 |
| Semaglutide | $149/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #169 · C
Strengths
- Sublingual ODT tablets offered as needle-free alternative
- Broad GLP-1 menu: semaglutide, tirzepatide, and retatrutide
- Transparent pricing: $150 starting dose, plans from $149/mo
- Led by board-certified physician/surgeon with 25+ years experience
- No contracts; flexible weekly, bi-weekly, or monthly cadence
Where it loses points
- Specific dose-tier pricing beyond starting plan not detailed
- Compounded vs brand not explicitly stated for all meds
- Smaller clinic vs national telehealth brands
- State licensing list not published
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.